Sanofi CEO: Vaccines business 'continues to deliver'

Sanofi Pasteur

Sanofi continues to lean on its vaccines offerings as other areas struggle. The French pharma’s vaccines unit Sanofi Pasteur “continues to deliver” and posted “good growth” in Q1, CEO Olivier Brandicourt told investors in discussing the results.

Driven by increased sales for polio, pertussis and Hib vaccines in emerging markets and Menactra's performance in the U.S., Sanofi grew vaccine sales 8.2% to €625 million ($719 million) for the quarter. It did this despite battling Pentacel supply constraints in the U.S., where overall vaccine sales were down 17.3%.

During the quarter, Sanofi recorded its first Dengvaxia sales, which rang in at €19 million and came from an immunization campaign just getting underway in the Philippines. On the earnings call, Brandicourt noted that the company recently submitted a "dossier for approval” for the first-in-its-class dengue vaccine to European regulators.


Veeva 2020 Unified Clinical Operations Survey

We believe you have the knowledge and expertise to make this year's Veeva 2020 Clinical Operations Report even more robust and insightful than the last. Please take a moment to share your opinion in this 10-minute survey. All qualified respondents will be entered to win a $500 Amazon gift card.

That vaccine got a boost last month from a WHO committee recommendation that countries where dengue is prevalent incorporate it into a comprehensive strategy to control the virus. With four approvals in hand, Sanofi anticipates further Dengvaxia regulatory blessings and new announcements surrounding immunization strategies. Analysts have said the vaccine could reach $1.4 billion in sales by 2020.

During the quarter, Sanofi decided to call off its vaccines JV with Merck in Europe, a move executives explained will allow the company to “allocate our resources behind our brand where we continue to see strong potential.”

Last year, Sanofi Pasteur grew sales 15% to €4.74 billion. The unit’s performance holds importance at the French pharma, where other revenues such as those from the flagship diabetes franchise have suffered in recent years. Diabetes and cardiovascular sales at Sanofi were down 5.8% in Q1.

- here's the release
- and a transcript of the conference call from Seeking Alpha

Related Articles:
Sanofi, Merck to split up their long-standing vaccines JV in Europe
Sanofi's Dengvaxia gets a boost from WHO recommendation
As corporate restructuring looms, Sanofi's vaccines deliver in 2015

Pictured is a Sanofi Pasteur R&D lab technician, courtesy of CNW Group and Sanofi Pasteur.


Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.